Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04210180 · ClinicalTrials.gov registry record · Phase 2
Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction
A Phase 2 study, sponsored by Rose Research Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT04210180 is a Phase 2 study that has completed, run by Rose Research Center. The registered enrollment target is 25 participants.
The verdict
NCT04210180, a Phase 2 study, has completed, sponsored by Rose Research Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This open-label study will explore the impact of varenicline on the process of switching from combustible cigarettes (CC) to an e-cigarette. Varenicline is currently the most efficacious single pharmacotherapy for smoking cessation, and through its actions as an agonist or partial agonist at various nicotinic acetylcholine receptor subtypes, serves to diminish the rewarding effects of cigarette smoking. Diminishing the rewarding effects of smoking might facilitate the transition from CC to e-cigarettes. On the other hand, varenicline might attenuate the rewarding effects of nicotine-containing e-cigarettes as well, which could hamper the transition. Thus, the study will provide important information about the actions of varenicline on CC as well as e-cigarettes. There is no therapeutic intent in that smokers' nicotine/tobacco dependence will not be treated; the goal is to switch from one form of nicotine/tobacco dependence (CC) to dependence on a different tobacco product (e-cigarettes).
Interventions
- DRUG Varenicline
- OTHER e-cigarette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-11-19 |
| Est. Completion | 2021-03-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04210180
The ClinicalTrials.gov registry entry for NCT04210180 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rose Research Center, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Varenicline is the first listed.
NCT04210180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04210180 about?
NCT04210180 is a clinical study titled "Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction". This open-label study will explore the impact of varenicline on the process of switching from combustible cigarettes (CC) to an e-cigarette. Varenicline is currently the most efficacious single pharmacotherapy for smoking cessation, and through its actions as an agonist or partial agonist at various...
What is the current status of trial NCT04210180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2019-11-19. Estimated completion is 2021-03-22.
What interventions are being tested in trial NCT04210180?
The interventions under investigation include: Varenicline (DRUG), e-cigarette (OTHER).
Who is sponsoring clinical trial NCT04210180?
This trial is sponsored by Rose Research Center, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.